Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2

Carcinogenesis

Volumn 28, Issue 5, 2007, Pages 977-987

  Hsieh, Yih Shou ^a   Chu, Shu Chen ^b   Yang, Shun Fa ^a   Chen, Pei Ni ^a   Liu, Yu Chuan ^a   Lu, Ko Hsiu ^a,c  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; GELATINASE A; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE B; SILIBININ; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ETS 1; UROKINASE; FOCAL ADHESION KINASE 1; PTK2 PROTEIN, HUMAN; SILYMARIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL ADHESION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; METASTASIS INHIBITION; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; BONE TUMOR; CELL SHAPE; CELL SURVIVAL; DISEASE COURSE; DRUG EFFECT; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BONE NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL SHAPE; CELL SURVIVAL; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FOCAL ADHESION KINASE 1; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; SILYMARIN; TRANSCRIPTION FACTOR AP-1; URINARY PLASMINOGEN ACTIVATOR;

EID: 34447094968     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl221     Document Type: Article

References (52)

1. Saller, R. et al. (2001) The use of silymarin in the treatment of liver diseases. Drugs, 61, 2035-2063.
2. Katiyar, S.K. et al. (1997) Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J. Natl Cancer Inst., 89, 556-566.
3. Kohno, H. et al. (2002) Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int. J. Cancer, 101, 461-468.
4. Singh, R.P. et al. (2002) Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res., 62, 3063-3069.
5. Mohan, S. et al. (2004) Silibinin modulates UVB-induced apoptosis via mitochondrial proteins, caspases activation, and mitogen-activated protein kinase signaling in human epidermoid carcinoma A431 cells. Biochem. Biophys. Res. Commun., 320, 183-189.
6. Tyagi, A.K. et al. (2002) Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin. Cancer Res., 8, 3512-3519.
7. Morazzoni, P. et al. (1995) Silybum marianum (Carduus marianus). Fitoterapia, 66, 3-42.
8. Agarwal, C. et al. (2003) Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma-HT-29 cells. Oncogene, 22 8271-8282.
9. Lorenz, D. et al. (1984) Pharmacokinetic studies with silymarin in human serum and bile. Methods Find. Exp. Clin. Pharmacol., 6 655-661.
10. Weyhenmeyer, R. et al. (1992) Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int. J. Clin. Pharmacol. Ther. Toxicol., 30, 134-138.
11. Zhao, J. et al. (1999) Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: Implications in cancer chemoprevention. Carcinogenesis, 20, 2101-2108.
12. Mackay, A.R. et al. (1990) Basement membrane type IV collagen degradation: Evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res., 50, 5997-6001.
13. Nelson, A.R. et al. (2000) Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol., 18, 1135-1149.
14. Johnsen, M. et al. (1998) Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr. Opin. Cell Biol., 10, 667-671.
15. Liabakk, N.B. et al. (1996) Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res., 56, 190-196.
16. Andreasen, P.A. et al. (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci., 57, 25-40.
17. Damiens, C. et al. (2000) Modulation by soluble factors of gelatinase activities released by osteoblastic cells. Cytokine, 12, 1727-1731
18. Ito, S. et al. (2002). Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J. Natl Cancer Inst., 94, 1080-1091.
19. Sebolt-Leopold, J.S. et al. (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer, 4, 937-947.
20. Chen, P.N. et al. (2005) Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem. Biol. Interact., 156, 141-150.
21. Huang, C. et al. (1998) Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc. Natl Acad. Sci. USA, 95, 156-161.
22. Yan, C. et al. (2001) KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha-induced block of p65/p50 nuclear translocation. J. Biol. Chem., 276, 1164-1172.
23. Testa, J.R. et al. (2001) AKT plays a central role in tumorigenesis. Proc. Natl Acad. Sci. USA, 98, 10983-10985.
24. Chu, S.C. et al. (2004) Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol. Carcinog., 40 143-149.
25. Hinck, L. et al. (1994) Dynamics of cadherin/catenin complex formation: Novel protein interactions and pathways of complex assembly. J. Cell. Biol., 125, 1327-1340.
26. Cazaubon, S. et al. (1997) Growth factor activity of endothelin-1 in primary astrocytes mediated by adhesion-dependent and -independent pathways. J. Neurosci., 17, 6203-6212.
27. Nojima, Y. et al. (1995) Integrin-mediated cell adhesion promotes tyrosine phosphorylation of p130Cas, a Src homology 3-containing molecule having multiple Src homology 2-binding motifs. J. Biol. Chem., 270, 15398-15402.
28. Mitra, S.K. et al. (2005) Focal adhesion kinase: In command and control of cell motility. Nat. Rev. Mol. Cell Biol., 6, 56-68.
29. Aplin, A.E. et al. (1999) Cell adhesion molecules, signal transduction and cell growth. Curr. Opin. Cell Biol., 11, 737-744.
30. Dorfman, H.D. et al. (1998) Osteosarcoma. In Dorfman, H.D. et al. (eds) Bone Tumors. Mosby, St Louis, pp. 128-252.
31. Weis, L. (1997) Common malignant bone tumors: Osteosarcoma. In Simon, M.A. et al. (eds) Surgery for Bone and Soft-Tissue Tumors. Lippincott-Raven, Philadelphia, NY, pp. 265-274.
32. Hong, W.K. et al. (1997) Recent advances in chemoprevention of cancer. Science, 278, 1073-1077.
33. Sporn, M.B. et al. (2000) Chemoprevention of cancer. Carcinogenesis, 21, 525-530.
34. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
35. Chen, P.N. et al. (2006) Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J. Dent. Res., 85 220-225.
36. Chu, S.C. et al. (2006) Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee. J. Rheumatol., 33, 311-317.
37. Hsieh, Y.S. et al. (2006) Clinical correlation with the PA/plasmin system in septic arthritis of the knee. Clin. Orthop. Relat. Res., 447, 172-178.
38. Hsieh, Y.S. et al. (2004) Expression changes of gelatinases in human osteoarthritic knees and arthroscopic debridement. Arthroscopy 20, 482-488.
39. Lu, K.H. et al. (2004) The significance of altered gelatinase expression in the synovium of patient with arthritic effusions. Clin. Rheumatol., 23, 21-26.
40. Pedersen, T.X. et al. (2005) Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis, 26, 1233-1240.
41. Carico, E. et al. (2001) E-cadherin and alpha-catenin expression during tumor progression of cervical carcinoma. Gynecol. Oncol., 80, 156-161.
42. Schlaepfer, D.D. et al. (1994) Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature, 372, 786-791.
43. Hood, J.D. et al. (2002) Role of integrins in cell invasion and migration. Nat. Rev. Cancer, 2, 91-100.
44. Westermarck, J. et al. (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J., 13 781-792.
45. Bergman, M.R. et al. (2003) A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem. J., 369, 485-496.
46. Philip, S. et al. (2003) Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J. Biol. Chem., 278, 14487-14497.
47. Rothhammer, T. et al. (2004) The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell. Mol. Life Sci., 61, 118-128.
48. Singh, R.P. et al. (2005) Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: Implications for angioprevention and antiangiogenic therapy. Oncogene, 24, 1188-1202.
49. Goetze, S. et al. (2001) TNFalpha induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2. Atherosclerosis 159, 93-101.
50. Logan, S.K. et al. (1996) Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors. J. Biol. Chem. 271, 774-782.
51. Dickinson, L.A. et al. (1999) Inhibition of Ets-1 DNA binding and ternary complex formation between Ets-1, NF-kappaB, and DNA by a designed DNA-binding ligand. J. Biol. Chem., 274, 12765-12773.
52. Bassuk, A.G. et al. (1997) Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. J. Virol., 71, 3563-3573.